Company Summary - Osmetech PLC (LSE:OMH)
2.00p
0.00p
FTSE AIM All Share Pharmaceuticals & BiotechnologyMarket cap: £23.073m
Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.
Sign-up to Premium's Free 7 Day trial See an improved company summary
Summary
Design, development, manufacture and sale of molecular diagnostics instruments and consumables enabling simple, rapid and cost effective DNA, RNA and protein testing
| Financials - Interim (17/9/2009) | ||
|---|---|---|
| Turnover | £m | 0.3 |
| Pre-tax Profit | £m | -5.54 |
| EPS | p | -0.62 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Chris Gleeson | Chairman |
| Dr. Jon Kayyem | Chief Executive |
| David Sandilands | Finance Director |
Products Brands & Subsidiaries
Products & Brands
A32/A50S Multisampler System; AromaScan A32/A8S Labstation; AromaScan-TD; CMS eSensor; OPTI CCA Blood Gas Analyzer; OPTI GENE...
Subsidiaries
Osmetech Inc; Osmetech Technology Inc; Clinical Micro Sensors Inc
Broker Sentiment (0 brokers)
No current consensus recommendation available.
| Heading | Date |
|---|---|
| Director/PDMR Shareholding | 08/10/2009 |
| Holding(s) in Company | 24/09/2009 |
| Re Agreement | 24/09/2009 |